Botanical Therapeutics for Parkinson's Disease

被引:1
|
作者
Li, Wen-wei [1 ,2 ,3 ]
机构
[1] Fudan Univ, Dept Neurol, Shanghai Publ Hlth Clin Ctr, Shanghai 201500, Peoples R China
[2] Fudan Univ, Zhongshan Hosp South Branch, Dept Neurol, Shanghai 201500, Peoples R China
[3] Fudan Univ, Inst Integrat Med, Inst Neurol, Shanghai 201500, Peoples R China
基金
中国国家自然科学基金;
关键词
Parkinson's disease; botanical therapeutics; Chinese medicine; neurotrophic activity; protein aggregation; neuroinflammation; TRADITIONAL CHINESE MEDICINE; CLINICAL DIAGNOSTIC-CRITERIA; ALPHA-SYNUCLEIN; WITHANIA-SOMNIFERA; MUCUNA-PRURIENS; DOUBLE-BLIND; AUTOPHAGY; DOPAMINE; CLEARANCE; MICROGLIA;
D O I
10.1007/s11655-020-3096-5
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Parkinson's disease (PD) was first formally described by James Parkinson in 1817, but the shaking of limbs was described in the literature of several ancient civilizations, such as ancient Chinese civilization and ancient Indian civilization. Historically, botanical drugs were used as the main source for the treatment of such kind of disorders. In Western countries, plant extracts also occupied an important place in the earlier medications of PD. With the adventure of synthetic drugs, the role of plant-derived drugs in management of PD has been diminished. Nowadays, there is still no cure for PD, dopaminergic (DA) medication is the treatment of choice, which is just designed to ameliorate symptoms of PD, and long-term use of DA medication will result in reduced efficacy and severe adverse reactions. It is necessary to explore new methods for the treatment of PD. Chinese medicine (CM) developed a holistic and unique theoretical system, and botanical drugs are widely used in practice for more than two millennia. Modern pharmacological studies have proved that Chinese herbs have potential therapeutic effects on PD, such as enhancing neurotrophic activity, clearing protein aggregates, regulating neuroinflammation, etc. All the advances provide us with hope for developing CM as a mainstream medication for treating PD.
引用
收藏
页码:405 / 411
页数:7
相关论文
共 50 条
  • [1] Botanical Therapeutics for Parkinson’s Disease
    Wen-wei Li
    [J]. Chinese Journal of Integrative Medicine, 2020, 26 : 405 - 411
  • [2] Botanical Therapeutics for Parkinson's Disease
    LI Wen-wei
    [J]. Chinese Journal of Integrative Medicine, 2020, 26 (06) : 405 - 411
  • [3] Experimental therapeutics of Parkinson's disease
    Henderson, JM
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (11) : 841 - 844
  • [4] Therapeutics in the neurorehabilitation of Parkinson's disease
    Colcher, A
    Stern, MB
    [J]. NEUROREHABILITATION AND NEURAL REPAIR, 1999, 13 (04) : 205 - 218
  • [5] Astrocytes and Therapeutics for Parkinson's Disease
    Rappold, Phillip M.
    Tieu, Kim
    [J]. NEUROTHERAPEUTICS, 2010, 7 (04) : 413 - 423
  • [6] Astrocytes and therapeutics for Parkinson’s disease
    Phillip M. Rappold
    Kim Tieu
    [J]. Neurotherapeutics, 2010, 7 : 413 - 423
  • [7] Cell Therapeutics in Parkinson’s Disease
    Olle Lindvall
    Anders Björklund
    [J]. Neurotherapeutics, 2011, 8 : 539 - 548
  • [8] Cell Therapeutics in Parkinson's Disease
    Lindvall, Olle
    Bjorklund, Anders
    [J]. NEUROTHERAPEUTICS, 2011, 8 (04) : 539 - 548
  • [9] Milestones in Parkinson's Disease Therapeutics
    Rascol, Olivier
    Lozano, Andres
    Stern, Matthew
    Poewe, Werner
    [J]. MOVEMENT DISORDERS, 2011, 26 (06) : 1072 - 1082
  • [10] NNR therapeutics for Parkinson's disease
    Strachan, Jon-Paul
    Heemstra, Ronald J.
    Bhatti, Balwinder S.
    Akireddy, Srinivasa
    Murthy, Srinivasa
    Miao, Lan
    Mazurov, Anatoly A.
    Kombo, David C.
    Speake, Jason D.
    Letchworth, Sharon R.
    Jordan, Kristen G.
    Zhang, Jenny
    Graef, John D.
    Szeliga, Ken T.
    James, John W.
    Johnston, Tom H.
    Huot, Philippe
    Fox, Susan H.
    Hill, Michael
    Brotchie, Jonathan M.
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244